Arvinas 10Q 2024 Q1 Quarterly report | ARVN Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accurate, adjuvant, administered, alternative, antitrust, AppTec, ASU, atirmociclib, biopharmaceutical, BIOSECURE, Centre, China, Chinese, cleared, closing, Codification, computation, confidentiality, credible, customary, deem, disaggregated, disaggregation, economic, emerge, enhanced, EOP, Evolving, failing, FASB, Fast, feedback, goal, good, health, healthy, idiopathic, indefinitely, independently, industry, integrity, interpolation, legislation, Leiden, Listing, long, multidomain, nominal, pending, Pharma, placement, political, private, procurement, pronouncement, proposed, relieve, rely, replaced, reversed, royalty, satisfaction, satisfactorily, scaffolding, segment, social, splice, strictly, Topic, transitioning, Treasury, undisclosed, unexpected, unpredictable, variant, variety, VERITAC, waiting, wholly, work, Wuxi

Removed: AACR, accompanied, acquired, adjustment, advantage, American, antigen, aromatase, authorized, biomarker, brain, capable, CBR, cellular, CHDI, CI, collection, commitment, comparability, Conference, confirmed, controlled, correct, correction, CTA, daily, deep, degraded, delivered, delivery, demonstrate, demonstrating, Diffuse, diversifying, engineered, error, exposure, gained, HTT, huntingtin, Huntington, improve, initiating, intermittent, key, lead, led, ligase, lower, machinery, mandatory, mHTT, misstate, mouse, mutant, mutated, mutation, Note, observed, overexpression, partial, peer, penetration, pharmacokinetic, point, potent, potently, preliminary, progressing, progression, PSA, radiographic, ranging, RAS, recent, resistance, response, rodent, satisfied, secondary, select, selective, showing, signaling, simplified, soluble, sparing, spending, spent, stable, step, submit, survival, tested, Tyrosine, unknown, utilized, vivo

Arvinas (ARVN) 10-Q2024 Q1 Quarterly report

Content analysis